Patents by Inventor Thomas Charles Boone
Thomas Charles Boone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230295267Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.Type: ApplicationFiled: June 7, 2023Publication date: September 21, 2023Applicant: AMGEN INC.Inventors: Jeonghoon SUN, Lei-Ting Tony TAM, Mark Leo MICHAELS, Thomas Charles BOONE, Rohini R. DESHPANDE, Yue-Sheng LI, Huiquan HAN
-
Patent number: 11685770Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.Type: GrantFiled: April 18, 2019Date of Patent: June 27, 2023Assignee: Amgen Inc.Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Mark Leo Michaels, Thomas Charles Boone, Rohini Deshpande, Yue-Sheng Li, Huiquan Han
-
Publication number: 20200283504Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.Type: ApplicationFiled: April 18, 2019Publication date: September 10, 2020Inventors: Jeonghoon SUN, Lei-Ting Tony TAM, Mark Leo MICHAELS, Thomas Charles BOONE, Rohini DESHPANDE, Yue-Sheng LI, Huiquan HAN
-
Publication number: 20190389932Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.Type: ApplicationFiled: April 18, 2019Publication date: December 26, 2019Inventors: Jeonghoon SUN, Lei-Ting Tony TAM, Mark Leo MICHAELS, Thomas Charles BOONE, Rohini DESHPANDE, Yue-Sheng LI, Huiquan HAN
-
Patent number: 10336820Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.Type: GrantFiled: December 2, 2016Date of Patent: July 2, 2019Assignee: Amgen Inc.Inventors: Thomas Charles Boone, Jonathan Daniel Oliner, Eunkyung Lee
-
Patent number: 10308704Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.Type: GrantFiled: January 22, 2016Date of Patent: June 4, 2019Assignee: Amgen Inc.Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Mark Leo Michaels, Thomas Charles Boone, Rohini Deshpande, Yue-Sheng Li, Huiquan Han
-
Patent number: 10189912Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: GrantFiled: January 12, 2017Date of Patent: January 29, 2019Assignee: AMGEN INC.Inventors: Kenneth W. Walker, Yue-Sheng Li, Thomas Charles Boone, George Doellgast, HoSung Min, Jane Talvenheimo, Taruna Arora, Frederick W. Jacobsen
-
Publication number: 20170190793Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: ApplicationFiled: January 12, 2017Publication date: July 6, 2017Applicant: AMGEN INC.Inventors: Kenneth W. WALKER, Yue-Sheng LI, Thomas Charles BOONE, George DOELLGAST (DECEASED), HoSung MIN, Jane TALVENHEIMO, Taruna ARORA, Frederick W. JACOBSEN
-
Publication number: 20170183391Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.Type: ApplicationFiled: January 22, 2016Publication date: June 29, 2017Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Mark Leo Michaels, Thomas Charles Boone, Rohini Deshpande, Yue-Sheng Li, Huiquan Han
-
Publication number: 20170081398Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.Type: ApplicationFiled: December 2, 2016Publication date: March 23, 2017Inventors: Thomas Charles Boone, Jonathan Daniel Oliner, Eunkyung Lee
-
Patent number: 9562108Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: GrantFiled: May 22, 2014Date of Patent: February 7, 2017Assignee: AMGEN INC.Inventors: Kenneth W. Walker, Yue-Sheng Li, Thomas Charles Boone, HoSung Min, Jane Talvenheimo, Taruna Arora, Frederick W. Jacobsen
-
Patent number: 9562107Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: GrantFiled: May 22, 2014Date of Patent: February 7, 2017Assignee: AMGEN INC.Inventors: Kenneth W. Walker, Yue-Sheng Li, Thomas Charles Boone, George Doellgast, HoSung Min, Jane Talvenheimo, Taruna Arora, Frederick W. Jacobsen
-
Publication number: 20160137718Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.Type: ApplicationFiled: January 22, 2016Publication date: May 19, 2016Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Mark Leo Michaels, Thomas Charles Boone, Rohini Deshpande, Yue-Sheng Li, Huiquan Han
-
Publication number: 20150175687Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: ApplicationFiled: October 30, 2014Publication date: June 25, 2015Inventors: Huiquan Han, Hosung Min, Thomas Charles Boone
-
Publication number: 20150044236Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: ApplicationFiled: May 22, 2014Publication date: February 12, 2015Applicant: AMGEN INC.Inventors: Kenneth W. WALKER, Yue-Sheng LI, Thomas Charles BOONE, HoSung MIN, Jane TALVENHEIMO, Taruna ARORA, Frederick W. JACOBSEN
-
Publication number: 20150044235Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: ApplicationFiled: May 22, 2014Publication date: February 12, 2015Applicant: Amgen Inc.Inventors: Kenneth W. WALKER, Yue-Sheng LI, Thomas Charles BOONE, George DOELLGAST (DECEASED), HoSung MIN, Jane TALVENHEIMO, Taruna ARORA, Frederick W. JACOBSEN
-
Patent number: 8920798Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: GrantFiled: November 20, 2012Date of Patent: December 30, 2014Assignee: Amgen Inc.Inventors: Huiquan Han, Hosung Min, Thomas Charles Boone
-
Publication number: 20140286953Abstract: The invention relates to purified, correctly folded hepcidin, antibodies that bind hepcidin, and methods of making and using such materials. Also provide are methods of treated hepcidin-related disorders.Type: ApplicationFiled: December 11, 2013Publication date: September 25, 2014Applicant: Amgen Inc.Inventors: Barbra Sasu, Mitsuru Haniu, Thomas Charles Boone, Xiao-juan Bi, Grace Ki Jeong Lee, Tara Arvedson, Aaron George Winters, Keegan Cooke, Jackie Z. Sheng
-
Publication number: 20140273089Abstract: The present invention provides Fibroblast Growth Factor Receptor-Like (FGFR-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGFR-L polypeptides. The inventio further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with FGFR-L polypeptides.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Applicant: AMGEN, INC.Inventors: Christiaan M. Saris, Sharon X. Mu, Min Xia, Thomas Charles Boone, Todd Covey
-
Patent number: 8629250Abstract: The invention relates to purified, correctly folded hepcidin, antibodies that bind hepcidin, and methods of making and using such materials. Also provide are methods of treated hepcidin-related disorders.Type: GrantFiled: January 30, 2008Date of Patent: January 14, 2014Assignee: Amgen Inc.Inventors: Barbra Sasu, Mitsuru Haniu, Thomas Charles Boone, Xiao-juan Bi, Grace Ki Jeong Lee, Tara Arvedson, Aaron George Winters, Keegan Cooke, Jackie Z. Sheng